Bio-Path Holdings Q2 2024 GAAP EPS $(1.16) Beats $(1.54) Estimate
Portfolio Pulse from Benzinga Newsdesk
Bio-Path Holdings (NASDAQ:BPTH) reported a Q2 2024 GAAP EPS of $(1.16), beating the analyst consensus estimate of $(1.54) by 24.68%. This represents an 89.1% improvement over the $(10.64) loss per share from the same period last year.
August 14, 2024 | 9:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Path Holdings reported a Q2 2024 GAAP EPS of $(1.16), beating the analyst consensus estimate of $(1.54) by 24.68%. This is a significant improvement from the $(10.64) loss per share in the same period last year.
The better-than-expected earnings per share (EPS) and significant year-over-year improvement are likely to positively impact BPTH's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100